← Eichor
Study identifier: NCT06626685 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Clonal Hematopoiesis of Indeterminate Potential in Heart Failure.

Condition: Heart Failure  ·  Sponsor: FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

PhaseN/A
Planned participants300
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is part of the Rico Macro-Project, a multidisciplinary research program promoted by FROM in collaboration with the ASST-PG23 and ATS Bergamo, aiming to investigate the role of clonal hematopoiesis on inflammation, studying in depth the mechanisms underlying the inflammatory process to determine their correlation with some important pathologies in different clinical fields (Hematology, Cardiology, Neurology, Pneumology, Gastroenterology, and Diabetology, etc.). In this context, the prospective observational study RICO-HF is developed. The RICO HF is the first project focused on CHIP and inflammation in the area of Cardiology, specifically in HF.

This description comes directly from the study's public registry record.

Talk to the study team

Antonello Gavazzi, MD  ·  +39 0352675134  ·  agavazzi@fondazionefrom.it

FENILI  ·  sperimentazioni@fondazionefrom.it

Always discuss trial participation with your own doctor first.

Locations (2)

ATS BERGAMO Agenzia di Tutela della SaluteBergamo, ItalyActive Not Recruiting
Asst Papa Giovanni Xxiii - Dip. Di CardiologiaBergamo, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06626685